Guobang Pharmaceutical announced that its revenue for the first half of 2026 was 3.142 billion yuan, an increase of 3.84% over the previous year. Net profit attributable to shareholders of listed companies was 341 million yuan, down 25.07% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 321 million yuan, down 26.46% year on year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.